MA26990A1 - Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine. - Google Patents

Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine.

Info

Publication number
MA26990A1
MA26990A1 MA27267A MA27267A MA26990A1 MA 26990 A1 MA26990 A1 MA 26990A1 MA 27267 A MA27267 A MA 27267A MA 27267 A MA27267 A MA 27267A MA 26990 A1 MA26990 A1 MA 26990A1
Authority
MA
Morocco
Prior art keywords
crf2r
methods
mass
function
corticotropin
Prior art date
Application number
MA27267A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Russell James Sheldon
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA26990A1 publication Critical patent/MA26990A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)

Abstract

PROCEDES POUR IDENTIFIER DES COMPOSES POUR REGULER LA MASSE OU LA FONCTION MUSCULAIRE EN UTILISANT DES RECEPTEURS DE FACTEURS LIBERATEURS DE CORTICOTROPINE THE PROCTER & GAMBLE COMPANY Invention de : ISFORT Robert SHELDON Russell Priorité : demande de brevet déposée aux Etats-Unis le 6 mars 2001 sous le no. 09/799,978 Procédés de criblage pour identifier des composés qui se lient à des récepteurs de facteurs 2 libérant de la corticotropine (CRF2R) ou activent ceux-ci et régulent ou régulent potentiellement la masse ou la fonction des muscles squelettiques in vivo. On décrit également des procédés de criblage pour identifier des composés qui prolongent ou augmentent l'activation des CRF2R ou de trajets de transduction de signaux des CRF2R, augmentent les CRF2R ou augmentent l'expression des CRF. On décrit également des compositions pharmaceutiques comprenant des agonistes de CRF2R, des anticorps aux CRF2R et des procédés permettant d'augmenter la masse ou la fonction des muscles squelettiques ou pour le traitement de l'atrophie des muscles squelettiques en utilisant des CRF2R comme cible pour l'intervention et des procédés de traitement de dystrophies usculaires.
MA27267A 2001-03-06 2003-08-07 Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine. MA26990A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/799,978 US6670140B2 (en) 2001-03-06 2001-03-06 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Publications (1)

Publication Number Publication Date
MA26990A1 true MA26990A1 (fr) 2004-12-20

Family

ID=25177205

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27267A MA26990A1 (fr) 2001-03-06 2003-08-07 Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine.

Country Status (28)

Country Link
US (3) US6670140B2 (fr)
EP (1) EP1379873B1 (fr)
JP (2) JP4331942B2 (fr)
KR (2) KR100598441B1 (fr)
CN (1) CN100520408C (fr)
AR (1) AR032957A1 (fr)
AT (1) ATE429242T1 (fr)
AU (1) AU2002303121B2 (fr)
BR (1) BR0207881A (fr)
CA (1) CA2439170C (fr)
CZ (1) CZ20032395A3 (fr)
DE (1) DE60232063D1 (fr)
ES (1) ES2325485T3 (fr)
HU (1) HUP0402173A2 (fr)
IL (1) IL157330A0 (fr)
MA (1) MA26990A1 (fr)
MX (1) MXPA03008114A (fr)
MY (1) MY134755A (fr)
NO (1) NO20033936L (fr)
NZ (1) NZ527124A (fr)
PE (1) PE20020993A1 (fr)
PL (1) PL367187A1 (fr)
RU (1) RU2260805C2 (fr)
SA (1) SA02230159B1 (fr)
SK (1) SK12132003A3 (fr)
TW (1) TWI227780B (fr)
WO (1) WO2002069908A2 (fr)
ZA (1) ZA200305642B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418144C (fr) * 2000-08-04 2013-06-18 Research Development Foundation Proteines urocortines et utilisations
US20040049009A1 (en) * 2000-09-22 2004-03-11 Klaus Eckart Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
US7815905B2 (en) * 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
US7982018B2 (en) * 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
KR20100017666A (ko) * 2007-05-23 2010-02-16 파마콤 엘엘씨 리간드 친화성이 개질된 ｇ단백질 공액형 수용체 및 그 용도
WO2010036918A2 (fr) * 2008-09-26 2010-04-01 University Of Massachusetts Récepteur intracellulaire d'adn
EP3369420A1 (fr) * 2010-12-23 2018-09-05 Amazentis SA Compositions et procédés pour améliorer la fonction mitochondriale ettraiter des maladies neurodégénératives et des troubles cognitifs
MX350355B (es) * 2011-11-14 2017-09-04 Regeneron Pharma Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a.
RU2517259C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
JP2015071549A (ja) * 2013-10-02 2015-04-16 株式会社ファンケル アトロジン−１抑制剤
RU2568903C2 (ru) * 2014-04-07 2015-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ оценки анаболического действия лекарственных препаратов
WO2016168613A1 (fr) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
CA3040889A1 (fr) 2016-10-20 2018-04-26 Cortene Inc. Methodes de traitement de maladies dues a une reponse au stress inadaptee
JP2021515003A (ja) 2018-03-01 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 体組成を変更するための方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415558A (en) * 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
WO1984001378A1 (fr) * 1982-09-29 1984-04-12 Karl P Lederis Peptides d'urotensine
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US4594329A (en) * 1984-05-14 1986-06-10 The Salk Institute For Biological Studies CRF analogs
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
DE3703340A1 (de) * 1987-02-04 1988-08-18 Dirck Dr Med Oppermann Pharmazeutische zubereitung zur behandlung der herzinsuffizienz
US4908352A (en) * 1987-09-28 1990-03-13 The Salk Institute For Biological Studies Urotensin peptides
US5109111A (en) * 1988-09-23 1992-04-28 The Salk Institute For Biological Studies CRF antagonists
US5278146A (en) * 1988-09-30 1994-01-11 The Salk Institute For Biological Studies CRF analogs
CA1340964C (fr) * 1988-09-30 2000-04-18 Jean E. F. Rivier Analogues du crf
US5235036A (en) * 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
US5493006A (en) * 1993-06-16 1996-02-20 The Salk Institute For Biological Studies Cyclic CRF analogs
US5728545A (en) * 1993-06-18 1998-03-17 The Salk Institute Of Biological Studies Cloning and recombinant production of CRF receptor (S)
US6495343B1 (en) * 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
EP0860501A3 (fr) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Récepteurs du facteur 2 libérant la corticotropine
ES2123269T5 (es) * 1994-06-14 2002-11-01 Neurocrine Biosciences Inc Receptores del factor 2 de liberacion de corticotropina.
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
AU6277796A (en) 1995-06-13 1997-01-15 Salk Institute For Biological Studies, The Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
US5888811A (en) * 1996-05-23 1999-03-30 Dupont Pharmaceuticals Company Corticotropin-releasing hormone receptor
EP1100819B1 (fr) * 1998-07-24 2007-02-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antagonistes specifiques du recepteur de la corticoliberine de type 2 (crfr2)
CA2418144C (fr) * 2000-08-04 2013-06-18 Research Development Foundation Proteines urocortines et utilisations
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Also Published As

Publication number Publication date
BR0207881A (pt) 2005-08-30
US7572768B2 (en) 2009-08-11
KR100596991B1 (ko) 2006-07-07
JP2004532394A (ja) 2004-10-21
JP4331942B2 (ja) 2009-09-16
US7063954B2 (en) 2006-06-20
CA2439170A1 (fr) 2002-09-12
PE20020993A1 (es) 2002-12-20
CN1820200A (zh) 2006-08-16
IL157330A0 (en) 2004-02-19
JP2009029816A (ja) 2009-02-12
NO20033936D0 (no) 2003-09-05
RU2260805C2 (ru) 2005-09-20
NO20033936L (no) 2003-11-05
US6670140B2 (en) 2003-12-30
EP1379873A2 (fr) 2004-01-14
ZA200305642B (en) 2004-06-22
NZ527124A (en) 2005-11-25
PL367187A1 (en) 2005-02-21
ES2325485T3 (es) 2009-09-07
US20060198842A1 (en) 2006-09-07
SK12132003A3 (sk) 2004-05-04
SA02230159B1 (ar) 2007-05-06
CA2439170C (fr) 2011-05-10
WO2002069908A3 (fr) 2003-03-20
WO2002069908A2 (fr) 2002-09-12
KR20030086289A (ko) 2003-11-07
US20030165807A1 (en) 2003-09-04
KR20060029704A (ko) 2006-04-06
MXPA03008114A (es) 2003-12-12
CN100520408C (zh) 2009-07-29
RU2003129500A (ru) 2005-03-10
DE60232063D1 (de) 2009-06-04
AU2002303121B2 (en) 2005-11-10
EP1379873B1 (fr) 2009-04-22
KR100598441B1 (ko) 2006-07-10
EP1379873A4 (fr) 2006-03-22
HUP0402173A2 (hu) 2005-01-28
TWI227780B (en) 2005-02-11
AR032957A1 (es) 2003-12-03
CZ20032395A3 (cs) 2004-01-14
US20040101911A1 (en) 2004-05-27
MY134755A (en) 2007-12-31
ATE429242T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
MA26990A1 (fr) Procedes d'identification de composes pour reguler la masse ou la fonction musculaire utilisant des recepteurs de facteur de liberation de la corticotropine.
Boie et al. Cloning and expression of a cDNA for the human prostanoid IP receptor.
EP0911321A3 (fr) Composés pour le traitement de l'ostéoporose
NO20022655L (no) <Beta>-2-adrenerge reseptoragonister
EP1308461A3 (fr) Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations
BRPI0410746A (pt) compostos e composições imunossupressoras
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
BG109311A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION
MA30555B1 (fr) Procedes d'utilisation du recepteur gpr119 pour identifier des composes utiles pour augmenter la masse osseuse chez un individu
WO2002085285A3 (fr) Methodes et compositions permettant de reguler la formation osseuse et cartilagineuse
ATE275562T1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
WO1998058911A3 (fr) Agonistes de prostaglandines
BR0215801A (pt) Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
ATE396969T1 (de) 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen
EP0801049A3 (fr) Dérivés de cyclopentanebutanol comme matières odorantes
ATE460153T1 (de) Riechstoffvorläufer
Mary et al. Modulation of T cell activation by differential regulation of the phosphorylation of two cytosolic proteins: implication of both Ca2+ and cyclic AMP-dependent protein kinases
WO2000002582A3 (fr) Traitement de la maladie coeliaque a l'aide d'antagonistes de l'interleukine-15
WO2002026781A3 (fr) Antagonistes du recepteur d'ige
ATE222901T1 (de) Carboxylsubstituierte chromanderivate zur verwendung als beta 3 adrenorezeptor-agonisten
NO20004801D0 (no) Glidemiddel pÕ basis av oktadekan
WO2004008153A3 (fr) Diagnostique et therapie des maladies associees au recepteur presume de neurotransmetteurs chez l'humain (pnr)
EP0922760A3 (fr) Animal transgénique n' exprimant pas de facteur inhibant l'ostéoclastogenèse (OCIF) endogène
WO2004003507A3 (fr) Procedes d'identification de composes regulant la masse ou la fonction musculaire au moyen de recepteurs de l'amyline
WO2007084648A3 (fr) Dimères mixtes 4-6 procyanidine et leur utilisation